Tag: study

  • China says vaccine scandal suspect free to re-offend

    The person at the center of an illegal vaccine scandal in China had been sentenced for similar crimes but was allowed to re-offend after being given a suspended sentence, the drug watchdog said on Thursday. The vaccines, including ones against meningitis, rabies and other illnesses, are suspected of being sold in dozens of provinces around…

  • Having a younger sibling may be good for your health

    A U.S. study suggests that younger siblings might be really good for your health. Children who didn’t welcome a baby brother or sister into the family before first grade had almost triple the odds of obesity compared with kids who experienced the birth of a sibling when they were around three to four years old,…

  • Having a younger sibling may be good for your health

    A U.S. study suggests that younger siblings might be really good for your health. Children who didn’t welcome a baby brother or sister into the family before first grade had almost triple the odds of obesity compared with kids who experienced the birth of a sibling when they were around three to four years old,…

  • Study shows how Zika virus could cause fetal brain defects

    By Andrew M. Seaman NEW YORK (Reuters) – The Zika virus is capable of quickly infecting and harming developing fetal brain cells, scientists said on Friday in a study that provides insight into how the virus might cause the birth defect microcephaly in fetuses exposed in the womb. The researchers said their study, published in…

  • Premature Birth Could Impact Fitness Later In Life

    (Reuters Health) – Young adults who were born prematurely may have weaker muscles than their peers born at full term, a Finnish study suggests.These young adults born preterm also considered themselves less physically fit, even though the study didn’t find their cardiorespiratory fitness levels to be much different than people who weren’t…

  • Novartis trial shows drug improves survival for AML patients

    ZURICH (Reuters) – Novartis' phase III study for its acute myeloid leukemia (AML) drug showed it improved overall survival by 23 percent for patients with FLT3 mutations, the Swiss drugmaker said on Sunday. Basel-based Novartis said the study was the first large controlled trial to show overall survival benefit in FLT3-mutated AML, and that worldwide…